The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced gastric or gastroesophageal junction cancer from JAVELIN solid tumor phase Ib trial: Analysis of safety and clinical activity.
 
Hyun Cheol Chung
Consulting or Advisory Role - Celltrion; Lilly; Merck; Taiho Pharmaceutical
Research Funding - Lilly (Inst)
 
Hendrik-Tobias Arkenau
No Relationships to Disclose
 
Lucjan Wyrwicz
Honoraria - Amgen; Merck; Roche
Consulting or Advisory Role - Amgen; Merck; Roche
 
Do-Youn Oh
No Relationships to Disclose
 
Keun-Wook Lee
Research Funding - AstraZeneca (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Roche (Inst); Taiho Pharmaceutical (Inst)
 
Jeffrey R. Infante
Consulting or Advisory Role - EMD Serono (Inst)
Research Funding - EMD Serono (Inst)
 
Sung Sook Lee
No Relationships to Disclose
 
Jeeyun Lee
No Relationships to Disclose
 
Ulrich Keilholz
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Merck KGaA; MSD Oncology; Novartis
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD Oncology; pfizer
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck Serono; MSD Oncology; MSD Oncology; Novartis
Research Funding - Merck Serono; Pfizer
 
Alain C. Mita
Speakers' Bureau - Genentech
 
Elizabeth R. Plummer
Honoraria - Bristol-Myers Squibb; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Biomarin; Clovis Oncology; Karus Therapeutics; Mission Therapeutics; MSD Oncology; Novartis; Roche/Genentech; Tesaro; Vertex
Speakers' Bureau - Novartis
Research Funding - AstraZeneca/MedImmune (Inst); Clovis Oncology (Inst); Eisai (Inst); Etherapeutics (Inst); Ipsen (Inst); vertex (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Roche/Genentech
 
Margaret Kemeny
No Relationships to Disclose
 
Bohuslav Melichar
Honoraria - Bristol-Myers Squibb; Merck; MSD; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; MSD; Novartis; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Roche
 
Denis Michel Smith
No Relationships to Disclose
 
Kevin M. Chin
Employment - EMD Serono
Stock and Other Ownership Interests - Bristol-Myers Squibb
Research Funding - EMD Serono (Inst)
 
Anja von Heydebreck
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Jean-Marie Cuillerot
Employment - EMD Serono
 
Yoon-Koo Kang
Consulting or Advisory Role - Lilly/ImClone; Novartis; Ono Pharmaceutical; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Bayer; Novartis; Roche/Genentech
 
Howard Safran
No Relationships to Disclose